Araris Biotech AG

We’re thrilled to be included as one of the top seven innovative companies revolutionizing antibody-drug conjugate (ADC) drug development in this report from Clarivate for Life Sciences & Healthcare. For more information, download the full report here: https://lnkd.in/eCSaAWtu

Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be a panelist on Drug Target Review's “Immunotherapy Advancements: Transforming Cancer Treatment” webinar on July 29th at 10am EDT. Join the webinar to hear more about Araris’ antibody-drug conjugates as a revolutionary approach in cancer treatment. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S

In case you missed it, we presented data at the @American Association for Cancer Research (AACR) Annual Meeting 2024 on two novel dual TOP1i ADCs targeting HER2 and NaPi2b that showed high stability and high anti-tumor activity in mouse models. Read more here: https://bit.ly/3Kp6tBq

We’re pleased to announce we’ve appointed Ulf Grawunder, Ph.D. to our scientific advisory board. His wealth of knowledge and experience in the #ADC space will be instrumental as we continue to innovate our proprietary ADC technology and develop our pipeline of next-generation ADC therapies. Read more: https://bit.ly/3xgdUaT

Our chief business officer, Filippo Mulinacci, and our acting-CEO and co-founder, Dragan Grabulovski, will be at BIO International Convention June 3-6, 2024 at the San Diego Convention Center. Contact us at partnering@ararisbiotech.com or send us an invite via the One-on-One BIO Partnering system to discuss our development of novel ADCs

In case you missed it, we’ll be in San Diego June 3-6, 2024 at the BIO International conference. Reach out to us to schedule a 1:1 meeting and learn more about our approach to ADC development: For more information, email us at partnering@ararisbiotech.com

Here at Araris, we are developing next-generation ADCs with improved efficacy and tolerability to create therapeutic options with potentially superior inhibition of tumor growth for patients. Learn more about our solution here: https://lnkd.in/eXFAHgxM

We are pioneering a proprietary ADC conjugation technology and linker-payload platform that will give us the ability to develop highly stable and precisely defined ADCs in only one step. Learn more here: https://lnkd.in/eXFAHgxM

The Araris team will be attending BIO International conference June 3-6, 2024 at the San Diego Convention Center. Reach out to us to set up 1:1 meetings to discuss more about how we’re pioneering the development of novel ADCs. Contact our CBO Filippo Mulinacci or send us an invite via the One-on-One BIO Partnering system.

Reflecting on an incredible experience at the 2024 American Association for Cancer Research conference! Our team was honored to connect with industry professionals who are united in the mission to drive progress toward better treatments and outcomes for patients living with #cancer.